Cellosaurus EW-7 (CVCL_1217)

Cell line name EW-7
Synonyms EW7; IARC-EW7; IARC-EW-7; IARC-EW 7
Accession CVCL_1217
Resource Identification Initiative To cite this cell line use: EW-7 (RRID:CVCL_1217)
Comments Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Disease Ewing sarcoma (NCIt: C4817)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP

Markers:
AmelogeninX
CSF1PO12
D13S3178
D16S53912
D5S81810,13
D7S8209
TH016
TPOX8,9
vWA16,18
Publications

PubMed=6713356; DOI=10.1016/0165-4608(84)90002-5
Turc-Carel C., Philip I., Berger M.-P., Philip T., Lenoir G.M.
Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12).
Cancer Genet. Cytogenet. 12:1-19(1984)

PubMed=11423975; DOI=10.1038/sj.onc.1204437
Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V., Weissman B.E., Delattre O.
Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.
Oncogene 20:3258-3265(2001)

PubMed=16631476; DOI=10.1016/j.cancergencyto.2005.11.006
Szuhai K., Ijszenga M., Tanke H.J., Rosenberg C., Hogendoorn P.C.W.
Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines.
Cancer Genet. Cytogenet. 166:173-179(2006)

PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622
Tirode F., Surdez D., Ma X., Parker M., Le Deley M.C., Bahrami A., Zhang Z., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S., Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O., Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M., Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V., Michon J., Marec-Berard P., Gut I., Downing J., Dyer M., Zhang J., Delattre O.
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Cancer Discov. 4:1342-1353(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line databases/resources Cosmic-CLP; 949160
GDSC; 949160
LINCS_LDP; LCL-1453
Chemistry resources ChEMBL-Cells; CHEMBL3308165
ChEMBL-Targets; CHEMBL2366112
Gene expression databases GEO; GSM1669790
Polymorphism and mutation databases Cosmic; 684071
Cosmic; 949160
Cosmic; 2250471